Carcinoid syndrome is a group of symptoms that can occur in patients suffering from carcinoid tumors which also called as metastatic neuroendocrine tumors. Carcinoid tumors are rare and these are slow growing tumors. Most of the tumors occur in gastrointestinal tract. According to FDA, carcinoid syndrome occurs in less than 10 percent of people suffering from carcinoid tumors, mostly after the tumor has spread to the liver. This syndrome causes overproduction of serotonin hormone which results in chronic diarrhea. Chronic diarrhea leads to malnutrition, weight loss, electrolyte imbalance and dehydration.
Carcinoid syndrome diarrhea is a rare condition. Treatment available for this condition are expected to get orphan drug status. Government and regulatory body support for development of orphan drug and incentives are expected to drive carcinoid syndrome treatment market. Government allow companies to set high price for the orphan drug and which in turn will generate high revenue. Ineffectiveness of diarrhea controlling agents in case of carcinoid syndromes diarrhea will also drive the growth of this market.
In 2018, the global Carcinoid Syndrome Diarrhea Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Carcinoid Syndrome Diarrhea Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Carcinoid Syndrome Diarrhea Treatment development in United States, Europe and China.
The key players covered in this study
Teva Pharmaceutical Industries
Market segment by Type, the product can be split into
Somatostatin Analog (SSA) Therapy
Market segment by Application, split into
Cancer Research Institutes
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Carcinoid Syndrome Diarrhea Treatment status, future forecast, growth opportunity, key market and key players.
To present the Carcinoid Syndrome Diarrhea Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Carcinoid Syndrome Diarrhea Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.